Albert Wiegman, born in Amsterdam, the Netherlands, became a pediatrician and member of the staff at the Amsterdam University Medical Centers in 1991. In 1993, he completed his sub-specialization in pediatric cardiology. In that year, the pediatric-lipid department came under his care. He started his research into the treatment of familial hypercholesterolemia in children, in close co-operation with prof John JP Kastelein, head of the department of vascular medicine. He brought the research to completion in his thesis: ‘Pediatric implications of heterozygous Familial Hypercholesterolemia’. In 2020, he was appointed associate professor and principal investigator.

Contributions

Efficacy and Safety of Inclisiran in Adolescents With Genetically Confirmed Homozygous Familial Hypercholesterolemia: Results From the Double- Blind, Placebo-Controlled Part of the ORION-13 Randomized TrialOtherPaediatric Lipid Working GroupProposal of a Familial Hypercholesterolemia Pediatric Diagnostic Score (FH-PeDS).Screening for FHPublicationPaediatric Lipid Working GroupChallenges for Children with FHRare Disease DayHoFH Awareness DayWebinars on-demandJoint FH Webinar series 2023: Let’s manage FH togetherPanel Discussion: Latest developments and real-world experience in the management of homozygous familial hypercholesterolaemia91st EAS Congress 2023Latest developments and real-world experience in the management of homozygous familial hypercholesterolaemiaReal-world experience with anti-ANGPTL3 antibody therapy in adolescent patients with homzygous familial hypercholesterolaemia91st EAS Congress 2023Latest developments and real-world experience in the management of homozygous familial hypercholesterolaemiaManaging lipids in children?91st EAS Congress 2023Clinical Seminar - Lipid management throughout a lifetimeFH in childrenAn introduction to FH for clinicians